Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence.

Foster NL, Hackett JS, White G, Chenevert S, Svarvar P, Bain L, Carrillo MC.

Alzheimers Dement. 2014 Jul;10(4):503-8. doi: 10.1016/j.jalz.2014.05.003.

PMID:
24985689
2.

Individual health services.

Schnell-Inderst P, Hunger T, Hintringer K, Schwarzer R, Seifert-Klauss VR, Gothe H, Wasem J, Siebert U.

GMS Health Technol Assess. 2011;7:Doc05. doi: 10.3205/hta000096. Epub 2011 Sep 15.

3.

[Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].

Hoomans T, van der Roer N, Severens JL, Delwel GO.

Ned Tijdschr Geneeskd. 2010;154:A958. Dutch.

PMID:
20699045
4.

Methods for the comparative evaluation of pharmaceuticals.

Zentner A, Velasco-Garrido M, Busse R.

GMS Health Technol Assess. 2005 Nov 15;1:Doc09.

5.

Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?

Drummond M.

J Health Polit Policy Law. 2013 Dec;38(6):1081-102. doi: 10.1215/03616878-2373148. Epub 2013 Aug 23.

PMID:
23974475
6.

[Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].

F├╝hrlinger S.

Wien Med Wochenschr. 2006 Dec;156(23-24):612-8. German.

PMID:
17211765
7.

Recommendations for best practices in the treatment of Alzheimer's disease in managed care.

Fillit HM, Doody RS, Binaso K, Crooks GM, Ferris SH, Farlow MR, Leifer B, Mills C, Minkoff N, Orland B, Reichman WE, Salloway S.

Am J Geriatr Pharmacother. 2006;4 Suppl A:S9-S24; quiz S25-S28.

PMID:
17157793
8.

Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.

Cheng JS, Lee MJ, Massicotte E, Ashman B, Gruenberg M, Pilcher LE, Skelly AC.

Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4. Review.

PMID:
21952186
9.

Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.

Frueh FW.

Value Health. 2013 Sep-Oct;16(6 Suppl):S27-31. doi: 10.1016/j.jval.2013.06.009.

10.

Evidence-based health care policy in reimbursement decisions: lessons from a series of six equivocal case-studies.

Van Herck P, Annemans L, Sermeus W, Ramaekers D.

PLoS One. 2013 Oct 30;8(10):e78662. doi: 10.1371/journal.pone.0078662. eCollection 2013.

11.

Evidence-based medicine: can it be applied to stimulation of erythropoiesis for patients with malignancy?

Rizzo JD.

Best Pract Res Clin Haematol. 2005;18(3):439-48. Review.

PMID:
15792918
12.

How to anticipate the assessment of the public health benefit of new medicines?

Massol J, Puech A, Boissel JP; Participants inRound Table No 7, Giens XXII.

Therapie. 2007 Sep-Oct;62(5):427-35. doi: 10.2515/therapie:2007071. Epub 2008 Jan 19.

PMID:
18206104
13.

American Society of Clinical Oncology guidance statement: the cost of cancer care.

Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, Ubel PA, Schnipper LE; American Society of Clinical Oncology.

J Clin Oncol. 2009 Aug 10;27(23):3868-74. doi: 10.1200/JCO.2009.23.1183. Epub 2009 Jul 6.

PMID:
19581533
14.

Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers.

de Groot S, Rijnsburger AJ, Versteegh MM, Heymans JM, Kleijnen S, Redekop WK, Verstijnen IM.

BMJ Open. 2015 Jul 28;5(7):e007241. doi: 10.1136/bmjopen-2014-007241. Review.

15.

Role of budget impact in drug reimbursement decisions.

Cohen JP, Stolk E, Niezen M.

J Health Polit Policy Law. 2008 Apr;33(2):225-47. doi: 10.1215/03616878-2007-054.

PMID:
18325899
16.

Drug reimbursement decision-making in Thailand, China, and South Korea.

Ngorsuraches S, Meng W, Kim BY, Kulsomboon V.

Value Health. 2012 Jan-Feb;15(1 Suppl):S120-5. doi: 10.1016/j.jval.2011.11.002.

17.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
18.

Limitations of evidence-based medicine: the role of experience and expert opinion.

Wenger DR.

J Pediatr Orthop. 2012 Sep;32 Suppl 2:S187-92. doi: 10.1097/BPO.0b013e318259f2ed.

PMID:
22890460
19.

Pricing and reimbursement of orphan drugs: the need for more transparency.

Simoens S.

Orphanet J Rare Dis. 2011 Jun 17;6:42. doi: 10.1186/1750-1172-6-42.

20.

Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.

Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, MacLeod S.

Can J Clin Pharmacol. 2009 Summer;16(2):e273-81; discussion e282-4. Epub 2009 May 13.

PMID:
19439771

Supplemental Content

Support Center